Comparison of autologous cell therapy and granulocyte-colony stimulating factor (G-CSF) injection vs. G-CSF injection alone for the treatment of acute radiation syndrome in a non-human primate model

Bertho, Jean-Marc; Frick, Johanna; Prat, Marie; Demarquay, Christelle; Dudoignon, N.; Trompier, F.; Gorin, Norbert‐Claude; Thierry, Dominique; Gourmelon, P.

doi:10.1016/j.ijrobp.2005.03.045

Cited by 45 publications

(43 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Thus, even in its optimal treatment regimen recombinant G-CSF, which on its own was able (under certain conditions) to rescue lethally irradiated mice and NHPs (Uckun et al, 1990;Bertho et al, 2005), was less effective compared with a single injection of CBLB502. Unlike CBLB502, G-CSF was incapable of rescuing mice when administered 24 h after lethal TBI (Uckun et al, 1990), the regimen used in the present study.…”

Section: Discussionmentioning

confidence: 99%

Identification of Granulocyte Colony-Stimulating Factor and Interleukin-6 as Candidate Biomarkers of CBLB502 Efficacy as a Medical Radiation Countermeasure

Krivokrysenko

Shakhov²,

Singh³

et al. 2012

J Pharmacol Exp Ther

100

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Identification of Granulocyte Colony-Stimulating Factor and Interleukin-6 as Candidate Biomarkers of CBLB502 Efficacy as a Medical Radiation Countermeasure

Krivokrysenko

Shakhov²,

Singh³

et al. 2012

J Pharmacol Exp Ther

100

View full text Add to dashboard Cite

“…Granulocyte colony-stimulating factor is effectively able to reduce the lethality of total-body radiation exposure by assisting in bone marrow recovery. 46 Another growth factor, keratinocyte growth factor (KGF), fibroblast growth factor 7 (FGF-7), stimulates many cellular processes, including differentiation, proliferation, DNA repair, and detoxification of ROS. 47 The characteristics of KGF are associated with the recovery of mucosa after ionizing radiation and prevent radiationinduced xerostomia 48 and mucositis.…”

Section: Mitigators Of Radiationmentioning

confidence: 99%

Treatment of Radiation Injury

Akita

2014

Advances in Wound Care

View full text Add to dashboard Cite

“…Survival significantly increased compared to controls. G-CSF generally enhanced hematopoietic recovery in all animal species and strains studied [48,51,64,67,68,[76][77][78][79][80][82][83][84][85][86][87]. The beneficial effects of G-CSF were measured as decreased duration of neutropenia, decreased time for neutrophil recovery, improved neutrophil nadir, increased WBC count, and increased granulocyte/macrophage colony-forming units (GM-CFU) in bone marrow.…”

Section: Studies With G-csfmentioning

confidence: 99%

Colony-stimulating factors for the treatment of the hematopoietic component of the acute radiation syndrome (H-ARS): A review

Singh

Newman²,

Seed³

2015

Cytokine

108

123

View full text Add to dashboard Cite

One of the greatest national security threats to the United States is the detonation of an improvised nuclear device or a radiological dispersal device in a heavily populated area. As such, this type of security threat is considered to be of relatively low risk, but one that would have an extraordinary high impact on health and well-being of the US citizenry. Psychological counseling and medical assessments would be necessary for all those significantly impacted by the nuclear/radiological event. Direct medical interventions would be necessary for all those individuals who had received substantial radiation exposures (e.g., >1 Gy). Although no drugs or products have yet been specifically approved by the United States Food and Drug Administration (US FDA) to treat the effects of acute radiation syndrome (ARS), granulocyte colony-stimulating factor (G-CSF), granulocyte macrophage colony-stimulating factor (GM-CSF), and pegylated G-CSF have been used off label for treating radiation accident victims. Recent threats of terrorist attacks using nuclear or radiologic devices makes it imperative that the medical community have up-to-date information and a clear understanding of treatment protocols using therapeutically effective recombinant growth factors and cytokines such as G-CSF and GM-CSF for patients exposed to injurious doses of ionizing radiation. Based on limited human studies with underlying biology, we see that the recombinants, G-CSF and GM-CSF appear to have modest, but significant medicinal value in treating radiation accident victims. In the near future, the US FDA may approve G-CSF and GM-CSF as ‘Emergency Use Authorization’ (EUA) for managing radiation-induced aplasia, an ARS-related pathology. In this article, we review the status of growth factors for the treatment of radiological/nuclear accident victims.

show abstract

Comparison of autologous cell therapy and granulocyte-colony stimulating factor (G-CSF) injection vs. G-CSF injection alone for the treatment of acute radiation syndrome in a non-human primate model

Cited by 45 publications

References 35 publications

Identification of Granulocyte Colony-Stimulating Factor and Interleukin-6 as Candidate Biomarkers of CBLB502 Efficacy as a Medical Radiation Countermeasure

Identification of Granulocyte Colony-Stimulating Factor and Interleukin-6 as Candidate Biomarkers of CBLB502 Efficacy as a Medical Radiation Countermeasure

Treatment of Radiation Injury

Colony-stimulating factors for the treatment of the hematopoietic component of the acute radiation syndrome (H-ARS): A review

Contact Info

Product

Resources

About